Quest PharmaTech Announces Allowance of US Patent for the use of Immunotherapeutic Antibodies in Combination with Chemotherapy for the Treatment of Cancer
TSX Venture: QPT
EDMONTON, July 21, 2011 /PRNewswire/ – Quest PharmaTech Inc. (TSXV: QPT)
(“Quest” or the “Company”), a pharmaceutical company developing and
commercializing products for the treatment of cancer, today announced
that it has received notice of allowance for U.S. Patent Application
10/831,886 entitled: “Combination Therapy for Treating Disease” (the
“Patent”). The Patent covers the use of monoclonal antibodies capable
of targeting tumor antigens CA 125, MUC1, CA 19.9, TAG-72 and prostate
specific antigen, which are presented in ovary, breast, lung, pancreas,
stomach and prostate cancers, respectively, in combination with a
chemotherapeutic drug to treat cancer.
The Company’s technology platform was based on the observation that its
lead product, Oregovomab, when used as mono-immunotherapy during
watchful waiting period in ovarian cancer patients was unable to meet
progression free survival endpoint. However, when Oregovomab was
administered in combination with front-line carboplatin-paclitaxel, the
combination resulted in a more vigorous immune response, which in turn
consistently correlated with favorable clinical outcome in a 40 patient
clinical trial. An enhanced immune response was also observed with
anti-MUC1 antibody and another chemotherapeutic agent, gemcitabine, in
a pancreatic cancer animal model. In addition to the use of
chemotherapeutic agents to enhance immune response, Quest has
successfully used photosensitizer, SL052 as well as a TLR3 agonist,
Ampligen in preclinical settings.
The allowance of the Patent by the U.S. Patent Office provides broad
coverage to Quest’s Combination Therapy Technology Platform,
complementing the corresponding patents already issued in Europe and
Australia. In addition, Quest has thirteen issued patents and five
pending patent applications in the U.S. to protect various aspects of
The Company is in the process of translating its valuable intellectual
property into commercial success by conducting three carefully planned
proof-of-concept clinical trials to establish the superiority of the
combinatorial immunotherapy either with front-line chemotherapy
consisting of carboplatin/paclitaxel in ovarian cancer or gemcitabine
in pancreatic cancer or with the addition of a TLR3 agonist, Ampligen.
The Company hopes that successful results from these studies will lead
to the design of a definitive product registration study.
About Quest PharmaTech Inc.
Quest is a publicly traded, Alberta-based biotechnology company
committed to the development and commercialization of oncology product
candidates. It is developing a series of products for the treatment of
cancer based on its pipeline of SonoLight compounds, and monoclonal
antibodies that target certain tumor antigens that are presented in a
variety of cancers. Quest believes that by combining these antibodies
with other cancer therapies such as chemotherapy or photodynamic
therapy, it can potentially further complement and enhance treatment
outcomes compared to antibody treatment alone.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE Quest PharmaTech Inc.